Gyorgy Frendl, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 8 | 2020 | 1967 | 1.210 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2014 | 341 | 1.050 |
Why?
|
| Atrial Flutter | 2 | 2014 | 264 | 0.820 |
Why?
|
| Pulmonary Atelectasis | 1 | 2022 | 145 | 0.790 |
Why?
|
| Electric Countershock | 2 | 2014 | 535 | 0.770 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2014 | 790 | 0.710 |
Why?
|
| Thrombelastography | 1 | 2019 | 163 | 0.610 |
Why?
|
| Sepsis | 6 | 2022 | 2589 | 0.570 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2019 | 3526 | 0.530 |
Why?
|
| Pneumonectomy | 4 | 2020 | 1093 | 0.450 |
Why?
|
| Thromboembolism | 1 | 2019 | 983 | 0.430 |
Why?
|
| Interleukin-6 | 2 | 2022 | 3199 | 0.430 |
Why?
|
| Pleural Neoplasms | 2 | 2020 | 607 | 0.420 |
Why?
|
| Antithrombins | 2 | 2013 | 304 | 0.380 |
Why?
|
| Catheter Ablation | 2 | 2014 | 2746 | 0.380 |
Why?
|
| Patient Simulation | 1 | 2013 | 308 | 0.370 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 316 | 0.360 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 484 | 0.360 |
Why?
|
| Intensive Care Units | 7 | 2022 | 3679 | 0.350 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2012 | 475 | 0.330 |
Why?
|
| Receptors, GABA-A | 1 | 2013 | 627 | 0.330 |
Why?
|
| Anesthetics | 1 | 2014 | 538 | 0.330 |
Why?
|
| Thrombosis | 1 | 2022 | 2966 | 0.320 |
Why?
|
| Anesthesiology | 2 | 2016 | 1043 | 0.300 |
Why?
|
| Benzodiazepines | 1 | 2013 | 1101 | 0.300 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 1123 | 0.290 |
Why?
|
| Postoperative Complications | 8 | 2024 | 15244 | 0.280 |
Why?
|
| Creatinine | 1 | 2012 | 1916 | 0.280 |
Why?
|
| Mesothelioma | 1 | 2012 | 818 | 0.270 |
Why?
|
| Interleukin-3 | 3 | 1992 | 441 | 0.260 |
Why?
|
| Atrial Fibrillation | 2 | 2014 | 5019 | 0.260 |
Why?
|
| Delirium | 1 | 2016 | 1608 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2195 | 0.230 |
Why?
|
| Cisplatin | 3 | 2020 | 1637 | 0.220 |
Why?
|
| Peptide Fragments | 2 | 2013 | 5095 | 0.220 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 4823 | 0.200 |
Why?
|
| Hirudins | 2 | 2013 | 182 | 0.190 |
Why?
|
| Echocardiography | 1 | 2013 | 5097 | 0.190 |
Why?
|
| Computer Simulation | 2 | 2013 | 6191 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2003 | 609 | 0.190 |
Why?
|
| Anesthesia, Conduction | 1 | 2022 | 238 | 0.170 |
Why?
|
| Macrophage Activation | 3 | 1992 | 558 | 0.170 |
Why?
|
| Positive-Pressure Respiration | 1 | 2022 | 632 | 0.160 |
Why?
|
| Critical Illness | 2 | 2022 | 2665 | 0.160 |
Why?
|
| Baths | 1 | 2018 | 54 | 0.160 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 15056 | 0.150 |
Why?
|
| Kidney | 3 | 2019 | 7167 | 0.150 |
Why?
|
| Theophylline | 1 | 2017 | 132 | 0.150 |
Why?
|
| Cross Infection | 2 | 2018 | 1413 | 0.140 |
Why?
|
| Chlorhexidine | 1 | 2018 | 162 | 0.140 |
Why?
|
| Serum | 1 | 2017 | 212 | 0.140 |
Why?
|
| Humans | 45 | 2024 | 742088 | 0.130 |
Why?
|
| Lung Diseases | 2 | 2017 | 1884 | 0.130 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1995 | 112 | 0.130 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2016 | 73 | 0.130 |
Why?
|
| Resuscitation | 1 | 2019 | 657 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2002 | 1252 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2014 | 3740 | 0.120 |
Why?
|
| Goals | 1 | 2019 | 705 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2017 | 502 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1126 | 0.110 |
Why?
|
| Complement Activation | 1 | 1995 | 452 | 0.110 |
Why?
|
| Critical Care | 4 | 2018 | 2640 | 0.110 |
Why?
|
| Macrophages | 4 | 1992 | 5655 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 365 | 0.110 |
Why?
|
| Thoracostomy | 1 | 2013 | 72 | 0.110 |
Why?
|
| Cefazolin | 1 | 2013 | 96 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2016 | 379 | 0.110 |
Why?
|
| Chest Tubes | 1 | 2013 | 150 | 0.110 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 546 | 0.110 |
Why?
|
| Nitric Oxide | 3 | 2003 | 2128 | 0.100 |
Why?
|
| Acetaminophen | 1 | 2016 | 544 | 0.100 |
Why?
|
| Preoperative Period | 1 | 2014 | 546 | 0.100 |
Why?
|
| Lung | 2 | 2024 | 9826 | 0.100 |
Why?
|
| Pharmacists | 1 | 2014 | 240 | 0.100 |
Why?
|
| Lipopolysaccharides | 4 | 2002 | 2211 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2024 | 77098 | 0.100 |
Why?
|
| Disease Progression | 2 | 2018 | 13256 | 0.100 |
Why?
|
| Video Recording | 1 | 2016 | 944 | 0.100 |
Why?
|
| Professional Role | 1 | 2014 | 306 | 0.100 |
Why?
|
| Bacteremia | 1 | 2018 | 962 | 0.100 |
Why?
|
| Vasodilation | 1 | 1995 | 944 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2017 | 3731 | 0.090 |
Why?
|
| Abdomen | 1 | 2017 | 1107 | 0.090 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1990 | 53 | 0.090 |
Why?
|
| Infection Control | 1 | 2018 | 962 | 0.090 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 274 | 0.090 |
Why?
|
| Drug Resistance, Fungal | 1 | 2010 | 51 | 0.090 |
Why?
|
| Interleukin-1 | 3 | 1992 | 1262 | 0.090 |
Why?
|
| Fungemia | 1 | 2010 | 53 | 0.090 |
Why?
|
| Partial Thromboplastin Time | 1 | 2011 | 206 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2014 | 501 | 0.090 |
Why?
|
| Fluconazole | 1 | 2010 | 146 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 1066 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2014 | 598 | 0.090 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 603 | 0.090 |
Why?
|
| Candida | 1 | 2010 | 172 | 0.090 |
Why?
|
| Hemodynamics | 2 | 2014 | 4197 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2014 | 23320 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2012 | 894 | 0.080 |
Why?
|
| Prospective Studies | 9 | 2024 | 53187 | 0.080 |
Why?
|
| Female | 24 | 2020 | 379592 | 0.080 |
Why?
|
| Middle Aged | 18 | 2020 | 213127 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 638 | 0.080 |
Why?
|
| Communication | 2 | 2014 | 3728 | 0.080 |
Why?
|
| Candidiasis | 1 | 2010 | 365 | 0.080 |
Why?
|
| Aged | 15 | 2020 | 162944 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2012 | 554 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 926 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2012 | 2295 | 0.070 |
Why?
|
| Orthopedic Procedures | 1 | 2017 | 1288 | 0.070 |
Why?
|
| Male | 22 | 2020 | 349538 | 0.070 |
Why?
|
| Iron | 1 | 2015 | 1773 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2017 | 5310 | 0.070 |
Why?
|
| Age Distribution | 1 | 2012 | 2900 | 0.070 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 381 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 6608 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 2002 | 0.070 |
Why?
|
| Taiwan | 2 | 2017 | 496 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 57683 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1990 | 1470 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 1911 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2010 | 729 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 994 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 7153 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2018 | 62966 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2012 | 1548 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2283 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2022 | 1839 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1538 | 0.060 |
Why?
|
| Risk Factors | 5 | 2024 | 72145 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 1995 | 3099 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2016 | 5978 | 0.060 |
Why?
|
| Consensus | 1 | 2012 | 2935 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 1171 | 0.050 |
Why?
|
| Carbon Monoxide | 2 | 2003 | 531 | 0.050 |
Why?
|
| Inflammation | 1 | 2022 | 10578 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 4455 | 0.050 |
Why?
|
| Linear Models | 1 | 2013 | 5948 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8328 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3038 | 0.050 |
Why?
|
| Heat-Shock Proteins | 2 | 2003 | 822 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39004 | 0.050 |
Why?
|
| Cytokines | 5 | 2003 | 7317 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2014 | 5774 | 0.050 |
Why?
|
| Phenotype | 1 | 2019 | 16331 | 0.050 |
Why?
|
| Survival Rate | 1 | 2014 | 12773 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 11001 | 0.040 |
Why?
|
| Receptors, Complement | 4 | 1995 | 264 | 0.040 |
Why?
|
| Incidence | 2 | 2022 | 20928 | 0.040 |
Why?
|
| Cholestasis | 1 | 2002 | 378 | 0.040 |
Why?
|
| Mixed Connective Tissue Disease | 2 | 1989 | 26 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2012 | 10248 | 0.040 |
Why?
|
| Acute-Phase Proteins | 2 | 2015 | 262 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2009 | 2527 | 0.040 |
Why?
|
| Interferon-gamma | 3 | 1992 | 3199 | 0.040 |
Why?
|
| Skin Care | 1 | 2018 | 49 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1990 | 1827 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13655 | 0.040 |
Why?
|
| Adult | 11 | 2024 | 213712 | 0.040 |
Why?
|
| Colloids | 1 | 2017 | 136 | 0.040 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 401 | 0.040 |
Why?
|
| Austria | 1 | 2016 | 201 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 10943 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2020 | 9846 | 0.030 |
Why?
|
| Drug Synergism | 2 | 1990 | 1791 | 0.030 |
Why?
|
| Respiration, Artificial | 2 | 2017 | 2566 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 250 | 0.030 |
Why?
|
| Zymosan | 1 | 1995 | 124 | 0.030 |
Why?
|
| Length of Stay | 2 | 2020 | 6294 | 0.030 |
Why?
|
| Complement Pathway, Alternative | 1 | 1995 | 126 | 0.030 |
Why?
|
| Bradykinin | 1 | 1995 | 214 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2022 | 1164 | 0.030 |
Why?
|
| Tidal Volume | 1 | 2017 | 489 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 1992 | 10163 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 2015 | 185 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 860 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 1995 | 264 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 363 | 0.030 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2016 | 417 | 0.030 |
Why?
|
| Lipocalins | 1 | 2015 | 170 | 0.030 |
Why?
|
| Substance P | 1 | 1995 | 335 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 29010 | 0.030 |
Why?
|
| Urinalysis | 1 | 2016 | 369 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 1995 | 351 | 0.030 |
Why?
|
| Animals | 8 | 2013 | 168561 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 40450 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 656 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2015 | 258 | 0.030 |
Why?
|
| Boston | 2 | 2016 | 9305 | 0.030 |
Why?
|
| Cells, Cultured | 5 | 2016 | 19223 | 0.030 |
Why?
|
| Pelvis | 1 | 2017 | 730 | 0.030 |
Why?
|
| Nephrosis, Lipoid | 1 | 2012 | 51 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 780 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 1992 | 199 | 0.030 |
Why?
|
| Pulmonary Circulation | 1 | 2014 | 739 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 1179 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2014 | 415 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1990 | 46 | 0.020 |
Why?
|
| Time Factors | 3 | 2017 | 40054 | 0.020 |
Why?
|
| Emergencies | 1 | 2017 | 1164 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2012 | 486 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 1992 | 675 | 0.020 |
Why?
|
| Monocytes | 3 | 1992 | 2593 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1990 | 148 | 0.020 |
Why?
|
| Propensity Score | 1 | 2017 | 1771 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1990 | 216 | 0.020 |
Why?
|
| Neutrophils | 2 | 1995 | 3711 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14720 | 0.020 |
Why?
|
| Apoptosis | 2 | 2003 | 9715 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 40955 | 0.020 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2011 | 203 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 885 | 0.020 |
Why?
|
| Biological Factors | 1 | 1990 | 164 | 0.020 |
Why?
|
| Health Services Research | 1 | 2016 | 1834 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1990 | 378 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2015 | 1532 | 0.020 |
Why?
|
| Young Adult | 4 | 2016 | 56350 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 1902 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1990 | 1581 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 1199 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8621 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 1653 | 0.020 |
Why?
|
| Growth Substances | 1 | 1990 | 783 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2017 | 2245 | 0.020 |
Why?
|
| Hypotension | 1 | 2014 | 880 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2012 | 13029 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 1650 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7470 | 0.020 |
Why?
|
| Hospitalization | 2 | 2017 | 10232 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2016 | 3678 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1990 | 902 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2009 | 398 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 1484 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1990 | 1368 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 6382 | 0.020 |
Why?
|
| Risk Management | 1 | 2009 | 571 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2009 | 510 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 1025 | 0.020 |
Why?
|
| Anesthesia | 1 | 2017 | 1548 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1995 | 2867 | 0.020 |
Why?
|
| Transfer Factor | 1 | 1985 | 5 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 3339 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 546 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4929 | 0.020 |
Why?
|
| Swine | 1 | 1995 | 5934 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 85649 | 0.020 |
Why?
|
| Hodgkin Disease | 2 | 1985 | 1413 | 0.020 |
Why?
|
| Skin | 1 | 2018 | 4353 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 1995 | 2145 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 1871 | 0.010 |
Why?
|
| Child | 1 | 2012 | 77478 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1995 | 3038 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2267 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 950 | 0.010 |
Why?
|
| Receptors, Complement 3b | 3 | 1989 | 145 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 1527 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2012 | 4211 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 2167 | 0.010 |
Why?
|
| Cell Movement | 1 | 1995 | 5212 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 1181 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4553 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 1873 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1989 | 1835 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1992 | 4024 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 11363 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2009 | 1100 | 0.010 |
Why?
|
| Contrast Media | 1 | 2014 | 5295 | 0.010 |
Why?
|
| Mice | 4 | 2012 | 81045 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2016 | 4681 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 12958 | 0.010 |
Why?
|
| Levamisole | 1 | 1980 | 35 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 13921 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18355 | 0.010 |
Why?
|
| Rosette Formation | 2 | 1989 | 153 | 0.010 |
Why?
|
| Massachusetts | 1 | 2012 | 8662 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1990 | 5519 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12017 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 2130 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 21719 | 0.010 |
Why?
|
| Phagocytosis | 3 | 1989 | 1538 | 0.010 |
Why?
|
| Gene Expression | 1 | 1990 | 7790 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 24265 | 0.010 |
Why?
|
| Cell Line | 1 | 1990 | 15994 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 2 | 1989 | 517 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 24913 | 0.010 |
Why?
|
| L-Selectin | 1 | 1995 | 213 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1995 | 210 | 0.010 |
Why?
|
| Receptors, Fc | 2 | 1989 | 540 | 0.010 |
Why?
|
| Hospitals | 1 | 2007 | 3937 | 0.010 |
Why?
|
| United States | 2 | 2012 | 69693 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1992 | 222 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20086 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1992 | 4414 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 1992 | 617 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 1599 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1992 | 23387 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1989 | 329 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1995 | 3139 | 0.000 |
Why?
|
| Integrins | 1 | 1992 | 845 | 0.000 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1990 | 525 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1989 | 865 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1989 | 1583 | 0.000 |
Why?
|
| Down-Regulation | 1 | 1990 | 3001 | 0.000 |
Why?
|
| Chemotaxis | 1 | 1985 | 607 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1990 | 2941 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1985 | 2614 | 0.000 |
Why?
|